Volume 9 Issue 1
Jan.  2018
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2018  >  9(1): 69-73
Li Jiang, Chen Xuchun, Meng Yiman, et al. Clinical analysis of de novo malignancies in recipients after renal transplantation[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 69-73. doi: 10.3969/j.issn.1674-7445.2018.01.010
Citation: Li Jiang, Chen Xuchun, Meng Yiman, et al. Clinical analysis of de novo malignancies in recipients after renal transplantation[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 69-73. doi: 10.3969/j.issn.1674-7445.2018.01.010
shu

Clinical analysis of de novo malignancies in recipients after renal transplantation

doi: 10.3969/j.issn.1674-7445.2018.01.010

  • Department of Hepatobiliary Surgery and Organ Transplantation, the First Affiliated Hospital of China Medical University, Shenyang 110001, China

More Information
  • Corresponding author: Yang Lei, E-mail:yanglei72@medmail.com.cn
  • Received Date: 2017-10-21
    Available Online: 2021-01-19
  • Publish Date: 2018-01-15
    Abstract
  •   Objective  To summarize the characteristics and treatment methods of de novo malignancies in recipients after renal transplantation.  Methods  Clinical data of 43 patients with de novo malignancies after renal transplantation among 759 recipients were analyzed retrospectively. Characteristics, treatment methods and prognosis of the de novo malignancies after renal transplantation were summarized.  Results  The incidence of de novo malignancies in recipients after renal transplantation was 5.7%. The age of onset was (52±11) years old, and the de novo malignancies was diagnosed in 13-193 months with the median of 60 months after renal transplantation. The 43 patients with de novo malignancies included 9 cases of primary renal carcinoma, 7 cases of bladder carcinoma, 6 cases of lung carcinoma, 5 cases of lymphoma, 4 cases of colorectal carcinoma, 4 cases of mammary carcinoma, 2 cases of skin carcinoma, 1 case of adrenal carcinoma, 1 case of gastric carcinoma, 1 case of primary carcinoma of liver, 1 case of pancreatic carcinoma, 1 case of scalp angiosarcoma and 1 case of meningioma, and they were treated by surgical procedure, adjusting immunosuppressive therapy, radiotherapy or chemotherapy after diagnosed. The postoperative 1-and 5-year survival rates were 81% and 63%, respectively.  Conclusions  The incidence of de novo malignancies in recipients after renal transplantation is higher than that in healthy subjects, and urological neoplasm is most common. Radical resection should be considered first, and antineoplastic combined therapy can be performed for the patients who cannot undergo surgery. Meanwhile, dosage of immunosuppressive agents can be reduced and medication regimens can be adjusted, thus effectively prolonging the survival time of patients.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    张健, 马麟麟, 孙雯, 等.肾移植术后肿瘤的发病特点及危险因素[J].临床和实验医学杂志, 2016, 15(22): 2277-2280. DOI: 10.3969/j.issn.1671-4695.2016.22.035.

    ZHANG J, MA LL, SUN W, et al. Characteristics and risk factors of tumor after renal transplantation[J]. J Clin Exp Med, 2016, 15(22): 2277-2280. DOI: 10.3969/j.issn.1671-4695.2016.22.035.
    [2]
    王超, 李涛, 张健, 等.中国肾移植术后并发恶性肿瘤趋势分析[J].器官移植, 2015, 6(3): 169-173.DOI: 10.3969/j.issn.1674-7445.2015.03.008.

    WANG C, LI T, ZHANG J, et al. Trend analysis of malignant tumor after renal transplantation in China[J]. Organ Transplant, 2015, 6(3): 169-173. DOI: 10.3969/j.issn.1674-7445.2015.03.008.
    [3]
    ZHANG J, MA L, XIE Z, et al. Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review[J]. Med Oncol, 2014, 31(7): 32. DOI: 10.1007/s12032-014-0032-6.
    [4]
    陈万青, 郑荣寿, 张思维, 等.2012年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2016, 25(1): 1-8.DOI: 10.11735/j.issn.1004-0242.2016.01.A001.

    CHEN WQ, ZHENG RS, ZHANG SW, et al. Report of cancer incidence and mortality in China, 2012[J]. Chin Cancer, 2016, 25(1):1-8.DOI: 10.11735/j.issn.1004-0242.2016.01.A001.
    [5]
    HOPE CM, COATES PT, CARROLL PR. Immune profiling cancer post transplantation[J]. World J Nephrol, 2015, 4(1): 41-56. DOI: 10.5527/wjn.v4.i1.41.
    [6]
    CHO YU, CHI HS, JANG S, et al. Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having post transplant lymphoproliferative disorders[J]. Am J Clin Pathol, 2014, 141(2): 268-274. DOI: 10.1309/AJCP9WYEXKOL9YUV.
    [7]
    NISHIKAWA J, YOSHIYAMA H, ⅡZASA H, et al. Epstein-barr virus in gastric carcinoma[J]. Cancers(Basel), 2014, 6(4): 2259-2274. DOI: 10.3390/cancers6042259.
    [8]
    OKADA S, GOTO H, YOTSUMOTO M. Current status of treatment for primary effusion lymphoma[J]. Intractable Rare Dis Res, 2014, 3(3): 65-74. DOI: 10.5582/irdr.2014.01010.
    [9]
    RIDRUEJO E. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma?[J]. Expert Opin Drug Saf, 2015, 14(3): 439-451. DOI: 10.1517/14740338.2015.998649.
    [10]
    WEI XL, QIU MZ, JIN Y, et al. Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases[J]. Br J Cancer, 2015, 112(7): 1283-1290. DOI: 10.1038/bjc.2014.406.
    [11]
    明英姿, 魏伟, 刘洪, 等.肾移植与BK病毒感染[J].器官移植, 2016, 7(6): 427-432. DOI: 10.3969/j.issn.1674-7445.2016.06.003.

    MING YZ, WEI W, LIU H, et al. Renal transplantation and BK virus infection[J]. Organ Transplant, 2016, 7(6): 427-432. DOI: 10.3969/j.issn.1674-7445.2016.06.003.
    [12]
    ROVIRA J, RENNER P, SABET-BAKTACH M, et al. Cyclosporine A inhibits the T-bet-dependent antitumor reseponse of CD8(+)T cell[J]. Am J Transplant, 2016, 16(4): 1139-1147. DOI: 10.1111/ajt.13597.
    [13]
    JIYAD Z, OLSEN CM, BURKE MT, et al. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and Meta-analysis[J]. Am J Transplant, 2016, 16(12): 3490-3503. DOI: 10.1111/ajt.13863.
    [14]
    ZILINSKA Z, SERSENOVA M, CHRASTINA M, et al. Occurrence of malignancies after kidney transplantation in adults: Slovak multicenter experience[J]. Neoplasma, 2017, 64(2): 311-317. DOI: 10.4149/neo_2017_220.
    [15]
    张健, 马麟麟, 解泽林, 等.我国肾移植术后新发恶性肿瘤总结分析[J].中华器官移植杂志, 2014, 35(12): 705-710. DOI: 10.3760/cma.j.issn.0254-1785.2014.12.001.

    ZHANG J, MA LL, XIE ZL, et al. Analysis of malignancy following renal transplantation in China[J]. Chin J Organ Transplant, 2014, 35(12): 705-710. DOI: 10.3760/cma.j.issn.0254-1785.2014.12.001.
    [16]
    ASCH WS, BIA MJ. Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening[J]. Adv Chronic Kidney Dis, 2014, 21(1): 106-113. DOI: 10.1053/j.ackd.2013.07.003.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (270) PDF downloads(22) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return